8-K: Invivyd Prices $125M Public Offering of Stock and Warrants
Public Offering Announcement
Invivyd, Inc. announced the pricing of a $125 million underwritten public offering of common stock and pre-funded warrants to fund pipeline development and commercial preparedness.
Summary
- Invivyd, Inc. priced an underwritten public offering of 44,000,000 shares of its common stock at $2.50 per share.
- The offering also included 6,000,000 pre-funded warrants to purchase common stock, priced at $2.4999 per warrant, with an exercise price of $0.0001 per share.
- The gross proceeds from this offering are expected to be approximately $125.0 million.
- Net proceeds to the company are approximately $117.2 million, after deducting underwriting discounts, commissions, and estimated offering expenses.
- The company granted the underwriters an option, exercisable for 30 days, to purchase up to an additional 7,500,000 shares of common stock at the public offering price.
- The offering is expected to close on or about November 19, 2025.
- Cantor Fitzgerald & Co. acted as sole book-running manager, and H.C. Wainwright & Co. acted as lead manager for the offering.
Sentiment
Score: 6
Explanation: The capital raise provides significant funding for key pipeline programs and commercial preparedness, which is positive for long-term growth. However, the substantial issuance of new shares and warrants will result in dilution for existing shareholders, balancing the overall sentiment to moderately positive.
Positives
- Secured approximately $117.2 million in net proceeds, significantly strengthening the company's cash position.
- Funds are allocated for commercial preparedness for the potential launch of VYD2311.
- Proceeds will support continued research and development for pipeline programs, including respiratory syncytial virus (RSV) and measles.
- The offering advances efforts of the Spike Protein Elimination and Recovery (SPEAR) Study Group related to Long COVID and COVID-19 Post-Vaccination Syndrome.
- Pre-funded warrants are exercisable at any time, do not expire, and can be exercised in cash or via a cashless method.
Negatives
- The issuance of 44,000,000 shares of common stock and warrants to purchase 6,000,000 shares will result in significant dilution for existing shareholders.
- The underwriters' option to purchase an additional 7,500,000 shares could lead to further dilution if exercised.
Risks
- General market conditions and stock price volatility may impact the company's valuation.
- Uncertainties related to financial markets, the medical community, and the global economy could affect operations.
- Instability in general business and economic conditions, including changes in inflation, interest rates, and the labor market, poses risks.
- The offering is subject to customary closing conditions, and there is no assurance it will be completed as anticipated.
- Delays in obtaining required stock exchange or other regulatory approvals could impact the offering or future operations.
- The company's actual results could differ materially from forward-looking statements due to various factors detailed in its SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025.
Future Outlook
Invivyd intends to use the net proceeds from the offering, combined with existing cash, for commercial preparedness for the potential launch of VYD2311, continued research and development for pipeline programs like RSV and measles, advancement of the SPEAR Study Group for Long COVID and COVID-19 Post-Vaccination Syndrome, and for general working capital and corporate purposes.
Management Comments
- Invivyd intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, for commercial preparedness for the potential launch of VYD2311, continued research and development related to its pipeline programs such as respiratory syncytial virus (RSV) and measles, continued advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and for working capital and other general corporate purposes.
Industry Context
Invivyd, Inc. is a biopharmaceutical company focused on protecting against serious viral infectious diseases, initially SARS-CoV-2. The company utilizes a proprietary integrated technology platform to develop and adapt best-in-class antibodies. This capital raise will support the advancement of its pipeline, including VYD2311, RSV, and measles programs, and efforts related to Long COVID, positioning it to potentially bring new therapies to market within the competitive biopharmaceutical landscape.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| New Securities Issued | Issuance of pre-funded warrants to purchase common stock, with specific terms regarding exercise price, adjustments, and beneficial ownership limitations (e.g., Maximum Percentage of 4.99% or 9.99%, adjustable to 19.99%). | 2025-11-17 | Introduces a new class of exercisable securities with anti-dilution provisions and beneficial ownership caps to manage control and regulatory compliance, potentially affecting the capital structure. |
| Lock-up Agreements | Directors and executive officers, and certain securityholders, are subject to a 60-day lock-up period restricting the sale or transfer of common stock and related securities. | 2025-11-17 | Aims to stabilize the stock price post-offering by preventing immediate sales by insiders, aligning their interests with long-term shareholders and reducing potential downward pressure on the stock. |
Stakeholder Impact
- Shareholders: Experience dilution from the issuance of new shares and warrants, but benefit from the strengthened financial position and funding for strategic initiatives that could drive future value.
- Employees: Benefit from continued funding for R&D programs, potentially ensuring job security and advancement opportunities within the company's pipeline development.
- Customers/Patients: Potential future benefit from the accelerated development and potential launch of new therapies like VYD2311, RSV, and measles treatments.
- Creditors: Improved financial health and liquidity from the capital raise may reduce credit risk.
Next Steps
- Closing of the public offering on or about November 19, 2025.
- Commercial preparedness for the potential launch of VYD2311.
- Continued research and development for respiratory syncytial virus (RSV) and measles pipeline programs.
- Continued advancement of the Spike Protein Elimination and Recovery (SPEAR) Study Group efforts related to assessing the effects of monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome.
Key Dates
| Date | Description |
|---|---|
| 2022-09-28 | Company's shelf registration statement on Form S-3 (File No. 333-267643) filed with the SEC. |
| 2022-10-05 | Company's shelf registration statement on Form S-3 declared effective by the SEC. |
| 2023-12-22 | Date of Controlled Equity OfferingSM Sales Agreement between the Company and Cantor. |
| 2024-03-01 | Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline. |
| 2024-12-31 | End of fiscal year for which Annual Report on Form 10-K was filed. |
| 2025-09-30 | End of quarterly period for which Quarterly Report on Form 10-Q was filed. |
| 2025-10-02 | Company's registration statement on Form S-3 (File No. 333-290685) filed with the SEC. |
| 2025-11-17 | Date of report (earliest event reported); Underwriting Agreement entered; Public offering launched and priced; Preliminary prospectus supplement and free writing prospectus filed. |
| 2025-11-19 | Expected closing date of the offering; Date of opinion of Hogan Lovells US LLP. |
| 2025-11-30 | Automatic termination date for lock-up agreements if Underwriting Agreement not executed by this date. |
| 2025-12-03 | Latest possible First Closing Date for the offering. |
Keywords
Invivyd, IVVD, Public Offering, Common Stock, Pre-Funded Warrants, Capital Raise, Biopharmaceutical, VYD2311, RSV, Measles, Long COVID, COVID-19 Post-Vaccination Syndrome, Monoclonal Antibody, SEC Filing, Underwriting Agreement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.